Diligence memo · auto-generated · as of July 2, 2026
Sirion Holdings, Inc.
Sirion Holdings, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Sirion Holdings, Inc. operates in Pharmaceuticals, based in Tampa.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sirion Holdings, Inc. has raised $30M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2009-10-15.
Most recent recorded round closed around 2009-10-15.
Valuation (modeled)modeled
Provath models Sirion Holdings, Inc. at approximately $941M (range $58M–$3.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.11× the median modeled value of Series B Pharmaceuticals companies in 2007–2009 (9 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 16.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 27.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 74% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Glycomimetics Inc, Avid Radiopharmaceuticals, Inc., Virdante Pharmaceuticals, Inc., Viamet Pharmaceuticals Inc, Aegerion Pharmaceuticals, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.